Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Dr Reddy's Laboratories Ltd

RDY ✓ COMPLIANT ☆ Track — members

NYSE · Healthcare · Pharmaceuticals ·

USA Large Cap Analyst: HOLD

Last Close

$12.27

▼ -1.21%

Market Cap $10.47B · Vol 707.92K

Key Metrics

P/E Ratio

29.47

FWD: 24.21

Market Cap

$10.47B

Large Cap

Div Yield

0.67%

Annual dividend

EPS Growth

-14.35%

YoY

RSI (14)

70.83

Momentum

Beta

0.29

vs Market

52W High

$15.67

21.70% below

52W Low

$11.36

8.01% above

Volume

707.92K

Avg 901.96K

P/B

2.86

Price-to-book

ROE

11.78%

Return on equity

Free Float

99.97%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Dr Reddy's Laboratories Ltd (RDY) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does RDY pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.41%

-4.44%

-9.04%

-13.22%

YTD

-12.61%

-13.04%

-13.68%

-2.17%

Financials & Valuation

TTM · Annual

Total Revenue	$3.59B
Net Income	$454.39M
Revenue Growth (YoY)	-14.53%
Gross Margin	52.77%
Operating Margin	14.81%
Net Profit Margin	12.64%
ROE	11.78%
ROA · ROIC	10.22% · 11.03%

P/E Ratio	29.47
Forward P/E (FY1)	24.21
PEG Ratio	-0.87
P/S	3.03
P/B	2.86
P/FCF	66.15
EPS Growth	-14.35%
Outstanding Shares	832.98M

Technical Indicators

50-Day SMA	$13.05
200-Day SMA	$13.57
RSI (14)	70.83
Beta	0.29
52-Week High	$15.67
52-Week Low	$11.36

Volume Today	707.92K
Avg Daily Volume (30D)	901.96K
Relative Volume	0.78x
Volatility (10D)	16.78
Volatility (30D)	37.30
Free Float	99.97%

Analyst Consensus

HOLD

Current Price $12.27

Mean Target $13.56

52W Low$11.36 52W High$15.67

Current

Target

$11.36 $15.67

Current Analyst target

+10.51% upside potential · 29 analysts

Identifiers

ExchangeNYSE

FIGIBBG001SHMCN3

ISINUS2561352038

CountryIndia

Sub-IndustryPharmaceuticals (NEC)

Earnings DateNov 2, 2026

TypeStocks

Instrument TypeADR American Depositary Receipt

Similar Halal Stocks

LLY Eli Lilly and Co -2.39% JNJ Johnson & Johnson -0.66% ABBV Abbvie Inc -0.54% NVS Novartis AG -0.55% NOVN.S Novartis AG -1.05%

Company Profile

Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.